Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Wood DE, Akerley W, et al. Non-small cell lung cancer, version 6.2015. J Natl Compr Canc Netw. 2015;13(5):515–524.
   PubMed Web of Science ®Google Scholar
• Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn. 2013;15(4):415–453.
   PubMed Web of Science ®Google Scholar
• Kris MG, Johnson BE, Kwatkowski DJ, et al. Identification of driver mutations in tumor specimens from 1,000 patients with adenocarcinoma: The NCI’s Cancer Mutation Consortium (LCMC). J Clin Oncol. 2011;29(suppl. 18). Abstract CRA7506.
   Web of Science ®Google Scholar
• Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–2394.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–2177.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370(13):1189–1197.
   PubMed Web of Science ®Google Scholar
• Masters GA, Temin S, Azzoli CG, et al. Systemic therapy for stage IV non-small-cell lung cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2015;33(30):3488–3515.
   PubMed Web of Science ®Google Scholar
• Gainor JF, Varghese AM, Ou SH, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res. 2013;19(15):4273–4281.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Bell DW, Lynch TJ, et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol. 2007;25(5):587–595.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957.
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–246.
   PubMed Web of Science ®Google Scholar
• Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16(2):141–151.
   PubMed Web of Science ®Google Scholar
• Khozin S, Blumenthal GM, Jiang X, et al. U.S. Food and Drug Administration approval summary: erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations. Oncologist. 2014;19(7):774–779.
   PubMed Web of Science ®Google Scholar
• Boehringer-Ingelheim press release: FDA approves GILOTRIFTM (afatinib) as first-line treatment for metastatic non-small cell lung cancer with common EGFR mutations. [cited 2016 Jan 21]. Avaible from: http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2013/07-12-13-fda-approves-gilotrif-afatinib-first-line-treatment-metastatic-non-small-cell-lung-cancer-common-egfr-mutations.html.
   Google Scholar
• FDA news release: FDA approves targeted therapy for first-line treatment of patients with a type of metastatic lung cancer. [cited 2016 Jan 21]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm454678.htm.
   Google Scholar
• Arcila ME, Chaft JE, Nafa K, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res. 2012;18(18):4910–4918.
   PubMed Web of Science ®Google Scholar
• Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 2005;65(5):1642–1646.
   PubMed Web of Science ®Google Scholar
• De Greve J, Moran T, Graas MP, et al. Phase II study of afatinib, an irreversible ERBB family blocker, in demographically and genotypically defined lung adenocarcinoma. Lung Cancer. 2015;88(1):63–69.
   PubMed Web of Science ®Google Scholar
• Li BT, Lee A, O’Toole S, et al. HER2 insertion YVMA mutant lung cancer: long natural history and response to afatinib. Lung Cancer. 2015;90(3):617–619.
   PubMed Web of Science ®Google Scholar
• Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693–1703.
   PubMed Web of Science ®Google Scholar
• Ali G, Proietti A, Pelliccioni S, et al. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment. Arch Pathol Lab Med. 2014;138(11):1449–1458.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Solomon B, Kenudson MM. Crizotinib and testing for ALK. J Natl Compr Canc Netw. 2011;9(12):1335–1341.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol. 2013;31(8):1105–1111.
   PubMed Web of Science ®Google Scholar
• Santarpia M, Altavilla G, Rosell R. Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer. Expert Rev Respir Med. 2015;9(3):255–268.
   PubMed Web of Science ®Google Scholar
• Ariad research and development: about brigatinib (AP26113). [cited 2016 Jan 21]. Available from: http://www.ariad.com/AP26113.
   Google Scholar
• Toyokawa G, Seto T, Takenoyama M, et al. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary? Cancer Metastasis Rev. 2015;34(4):797–805.
   PubMed Web of Science ®Google Scholar
• Zhang I, Zaorsky NG, Palmer JD, et al. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncol. 2015;16(13):e510–521.
   PubMed Web of Science ®Google Scholar
• West AH, Yamada SD, MacMahon H, et al. Unique metastases of ALK mutated lung cancer activated to the adnexa of the uterus. Case Rep Clin Pathol. 2014;1(2):151–154.
   PubMedGoogle Scholar
• Heist RS, Engelman JA. SnapShot: non-small cell lung cancer. Cancer Cell. 2012;21(3):448.e2.
   PubMedGoogle Scholar
• Ou SH, Tan J, Yen Y, et al. ROS1 as a ‘druggable’ receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway. Expert Rev Anticancer Ther. 2012;12(4):447–456.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963–1971.
   PubMed Web of Science ®Google Scholar
• Zhu Q, Zhan P, Zhang X, et al. Clinicopathologic characteristics of patients with ROS1 fusion gene in non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res. 2015;4(3):300–309.
   PubMedGoogle Scholar
• Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18(3):378–381.
   PubMed Web of Science ®Google Scholar
• Wang R, Hu H, Pan Y, et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol. 2012;30(35):4352–4359.
   PubMed Web of Science ®Google Scholar
• Song M, Kim SH, Yoon SK. Cabozantinib for the treatment of non-small cell lung cancer with KIF5B-RET fusion. An example of swift repositioning. Arch Pharm Res. 2015;38(12):2120–2123.
   PubMed Web of Science ®Google Scholar
• Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18(3):382–384.
   PubMed Web of Science ®Google Scholar
• Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012;18(3):375–377.
   PubMed Web of Science ®Google Scholar
• Drilon A, Wang L, Hasanovic A, et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 2013;3(6):630–635.
   PubMed Web of Science ®Google Scholar
• Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998–2006.
   PubMed Web of Science ®Google Scholar
• Sun Y, Ren Y, Fang Z, et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol. 2010;28(30):4616–4620.
   PubMed Web of Science ®Google Scholar
• Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin. Cancer Res. 2008;14(18):5731–5734.
   PubMed Web of Science ®Google Scholar
• Nguyen-Ngoc T, Bouchaab H, Adjei AA, et al. BRAF alterations as therapeutic targets in non-small-cell lung cancer. J Thorac Oncol. 2015;10(10):1396–1403.
   PubMed Web of Science ®Google Scholar
• Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol. 2011;29(15):2046–2051.
   PubMed Web of Science ®Google Scholar
• Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011;29(26):3574–3579.
   PubMed Web of Science ®Google Scholar
• Naoki K, Chen TH, Richards WG, et al. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res. 2002;62(23):7001–7003.
   PubMed Web of Science ®Google Scholar
• Planchard D, Kim TM, Mazieres J. Dabrafenib in patients with BRAF V600E-mutant advanced NSCLC: A multicenter, open-label, Phase II trial (BRF113928). Ann Oncol. 2014;25 (suppl. 4). 1-41-LBA38_PR
   Google Scholar
• Inman S OncLive: dabrafenib receives breakthrough designation for NSCLC. [cited 2016 Jan 21]. Available from: http://www.onclive.com/web-exclusives/Dabrafenib-Receives-Breakthrough-Designation-for-NSCLC#sthash.ggLpXltM.dpuf.
   Google Scholar
• Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524–5528.
   PubMed Web of Science ®Google Scholar
• Wang H, Daouti S, Li WH, et al. Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation. Cancer Res. 2011;71(16):5535–5545.
   PubMed Web of Science ®Google Scholar
• Hatzivassiliou G, Liu B, O’Brien C, et al. ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol Cancer Ther. 2012;11(5):1143–1154.
   PubMed Web of Science ®Google Scholar
• Vaishnavi A, Capelletti M, Le AT, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med. 2013;19(11):1469–1472.
   PubMed Web of Science ®Google Scholar
• Sharifnia T, Rusu V, Piccioni F, et al. Genetic modifiers of EGFR dependence in non-small cell lung cancer. Proc Natl Acad Sci U S A. 2014;111(52):18661–18666.
   PubMed Web of Science ®Google Scholar
• Farago AF, Le LP, Zheng Z, et al. Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer. J Thorac Oncol. 2015;10(12):1670–1674.
   PubMed Web of Science ®Google Scholar
• Kawakami H, Okamoto I, Okamoto W, et al. Targeting MET amplification as a new oncogenic driver. Cancers (Basel). 2014;6(3):1540–1552.
   PubMed Web of Science ®Google Scholar
• Beau-Faller M, Ruppert AM, Voegeli AC, et al. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort. J Thorac Oncol. 2008;3(4):331–339.
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol. 2009;27(10):1667–1674.
   PubMed Web of Science ®Google Scholar
• Jagadeeswaran R, Surawska H, Krishnaswamy S, et al. Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res. 2008;68(1):132–142.
   PubMed Web of Science ®Google Scholar
• Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 2005;65(4):1479–1488.
   PubMed Web of Science ®Google Scholar
• Ma PC, Kijima T, Maulik G, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 2003;63(19):6272–6281.
   PubMed Web of Science ®Google Scholar
• Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015;5(8):850–859.
   PubMed Web of Science ®Google Scholar
• Paik PK, Drilon A, Fan PD, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 2015;5(8):842–849.
   PubMed Web of Science ®Google Scholar
• Jenkins RW, Oxnard GR, Elkin S, et al. Response to crizotinib in a patient with lung adenocarcinoma harboring a MET splice site mutation. Clin Lung Cancer. 2015;16(5):e101–104.
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316(5827):1039–1043.
   PubMed Web of Science ®Google Scholar
• Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 2007;104(52):20932–20937.
   PubMed Web of Science ®Google Scholar
• Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240–2247.
   PubMed Web of Science ®Google Scholar
• Lovly CM, Horn L. Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC. Curr Treat Options Oncol. 2012;13(4):516–526.
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Arcila ME, Chmielecki J, et al. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin. Cancer Res. 2011;17(17):5530–5537.
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Tsai C, Shepherd FA, et al. AZD9291 in pre-treated T790M positive advanced NSCLC: AURA2 Phase II study. Presented at the 16th World Conference on Lung Cancer; 2015 Sep 6–9; Denver, CO. Abstract 1406.
   Google Scholar
• Sequist LV, Goldman JW, Wakelee HA. Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol. 2015;33(suppl):8001.
   Google Scholar
• Tan DS, Seto T, Leighl NB. First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M. J Clin Oncol. 2015;33(suppl):8013.
   Google Scholar
• Ercan D, Xu C, Yanagita M, et al. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov. 2012;2(10):934–947.
   PubMed Web of Science ®Google Scholar
• Ohashi K, Sequist LV, Arcila ME, et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A. 2012;109(31):E2127–133.
   PubMed Web of Science ®Google Scholar
• Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005;2(1):e17.
   PubMed Web of Science ®Google Scholar
• Klempner SJ, Bazhenova LA, Braiteh FS, et al. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI. Lung Cancer. 2015;89(3):357–359.
   PubMed Web of Science ®Google Scholar
• Alam N, Gustafson KS, Ladanyi M, et al. Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung. Clin Lung Cancer. 2010;11(5):E1–4.
   Google Scholar
• Kuiper JL, Ronden MI, Becker A, et al. Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor. J Clin Pathol. 2015;68(4):320–321.
   PubMed Web of Science ®Google Scholar
• Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662–673.
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Khuri FR. Second-generation ALK inhibitors: filling the non “MET” gap. Cancer Discov. 2014;4(6):634–636.
   PubMed Web of Science ®Google Scholar
• Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 2012;18(5):1472–1482.
   PubMed Web of Science ®Google Scholar
• Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med. 2012;4(120): 120ra17.
   PubMed Web of Science ®Google Scholar
• Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010;363(18):1734–1739.
   PubMed Web of Science ®Google Scholar
• Sun HY, Ji FQ. A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK. Biochem Biophys Res Commun. 2012;423(2):319–324.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Koivunen J, Ogino A, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011;71(18):6051–6060.
   PubMed Web of Science ®Google Scholar
• Puig De La Bellacasa R, Karachaliou N, Estrada-Tejedor R, et al. ALK and ROS1 as a joint target for the treatment of lung cancer: a review. Transl Lung Cancer Res. 2013;2(2):72–86.
   PubMedGoogle Scholar
• Roskoski R Jr. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. Pharmacol Res. 2013;68(1):68–94.
   PubMed Web of Science ®Google Scholar
• Awad MM, Shaw AT. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol. 2014;12(7):429–439.
   PubMedGoogle Scholar
• Zhang S, Wang F, Keats J, et al. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des. 2011;78(6):999–1005.
   PubMed Web of Science ®Google Scholar
• Ni Z, Zhang TC. Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer. J Mol Model. 2015;21(7):175.
   PubMed Web of Science ®Google Scholar
• Mok TS, Spigel DR, Felip E. ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). J Clin Oncol. 2015;33(suppl):8059.
   Google Scholar
• Felip E, Orlov S, Park K. ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33(suppl):8060.
   Google Scholar
• Gainor JF, Tan DS, De Pas T, et al. Progression-free and overall survival in ALK-positive NSCLC patients treated with sequential crizotinib and ceritinib. Clin. Cancer Res. 2015;21(12):2745–2752.
   PubMed Web of Science ®Google Scholar
• Hotta K, Hida T, Nakagawa K, et al. Updated data from JP28927 study of alectinib in ALK+ NSCLC patients with or without history of ALK inhibitor treatment. Presented at the 16th World Conference on Lung Cancer; 2015 Sep 6–9; Denver, CO. Abstract P3.01-020.
   Google Scholar
• Barlesi F, Dingemans AMC, Ou I et al. Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small cell lung cancer (NSCLC). Presented at the European Society for Clinical Oncology European Cancer Congress; 2015 Sep 25–29; Vienna, Austria. Abstract 3101.
   Google Scholar
• Shaw A, West H, Socinski MA et al. Updated efficacy/safety data from the phase 2 NP28761 study of alectinib in ALK+ NSCLC. Presented at the 16th World Conference on Lung Cancer; 2015 Sep 6–9; Denver, CO. Abstract 33.03.
   Google Scholar
• Gettinger SN, Bazhenova LA, Salgia R et al. Brigatinib (AP26113) efficacy and safety in ALK+ NSCLC: phase 1/2 trial results. Presented at the 16th World Conference on Lung Cancer; 2015 Sep 6–9; Denver, CO. Abstract 33.06.
   Google Scholar
• Toyokawa G, Inamasu E, Shimamatsu S, et al. Identification of a novel ALK G1123S mutation in a patient with ALK-rearranged non-small-cell lung cancer exhibiting resistance to ceritinib. J Thorac Oncol. 2015;10(7):e55–57.
   PubMed Web of Science ®Google Scholar
• Ou SH, Greenbowe J, Khan ZU, et al. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib. Lung Cancer. 2015;88(2):231–234.
   PubMed Web of Science ®Google Scholar
• Ignatius Ou SH, Azada M, Hsiang DJ, et al. Next-generation sequencing reveals a novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol. 2014;9(4):549–553.
   PubMed Web of Science ®Google Scholar
• Politi K, Gettinger S. Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer. Clin. Cancer Res. 2014;20(22):5576–5578.
   PubMed Web of Science ®Google Scholar
• Azzato EM, Deshpande C, Aikawa V, et al. Rare complex mutational profile in an ALK inhibitor-resistant non-small cell lung cancer. Anticancer Res. 2015;35(5):3007–3012.
   PubMed Web of Science ®Google Scholar
• NCCN. Clinical practice. Guidelines in oncology. Non-small Cell Lung Cancer, Version. 2015;5: NSCL-16 and NSCL-H.
   Google Scholar
• Sun H, Li Y, Tian S, et al. P-loop conformation governed crizotinib resistance in G2032R-mutated ROS1 tyrosine kinase: clues from free energy landscape. PLoS Comput Biol. 2014;10(7):e1003729.
   PubMed Web of Science ®Google Scholar
• Awad MM, Katayama R, McTigue M, et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med. 2013;368(25):2395–2401.
   PubMed Web of Science ®Google Scholar
• Davare MA, Vellore NA, Wagner JP, et al. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors. Proc Natl Acad Sci U S A. 2015;112(39):E5381–390.
   PubMed Web of Science ®Google Scholar
• Zou HY, Li Q, Engstrom LD, et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc Natl Acad Sci U S A. 2015;112(11):3493–3498.
   PubMed Web of Science ®Google Scholar
• Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29(22):3085–3096.
   PubMed Web of Science ®Google Scholar
• Shi H, Moriceau G, Kong X, et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012;3:724.
   PubMed Web of Science ®Google Scholar
• Rudin CM, Hong K, Streit M. Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer. J Thorac Oncol. 2013;8(5):e41–42.
   PubMed Web of Science ®Google Scholar
• Planchard D, Groen HJM, Kim TM. Interim results of a phase II study of the BRAF inhibitor dabrafenib in combination with the MEK inhibitor trametinib in patients with BRAF V600E-mutated NSCLC. J Clin Oncol. 2015;33(suppl):8006.
   Google Scholar
• Falchook GS, Trent JC, Heinrich MC, et al. BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget. 2013;4(2):310–315.
   PubMed Web of Science ®Google Scholar
• Cepero V, Sierra JR, Corso S, et al. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res. 2010;70(19):7580–7590.
   PubMed Web of Science ®Google Scholar
• Tiedt R, Degenkolbe E, Furet P, et al. A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients. Cancer Res. 2011;71(15):5255–5264.
   PubMed Web of Science ®Google Scholar
• Vatrano S, Righi L, Vavala T, et al. Molecular and histological changes in post-treatment biopsies of non-squamous non-small cell lung cancer: a retrospective study. Target Oncol. 2016;11(2):157–166.
   PubMed Web of Science ®Google Scholar
• Aisner DL, Marshall CB. Molecular pathology of non-small cell lung cancer: a practical guide. Am J Clin Pathol. 2012;138(3):332–346.
   PubMed Web of Science ®Google Scholar
• Salgia R. Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach. Future Oncol. 2015;11(3):489–500.
   PubMed Web of Science ®Google Scholar
• Khoo C, Rogers TM, Fellowes A, et al. Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond. Transl Lung Cancer Res. 2015;4(2):126–141.
   PubMed Web of Science ®Google Scholar
• Abe H, Kawahara A, Azuma K, et al. Heterogeneity of anaplastic lymphoma kinase gene rearrangement in non-small-cell lung carcinomas: a comparative study between small biopsy and excision samples. J Thorac Oncol. 2015;10(5):800–805.
   PubMed Web of Science ®Google Scholar
• Sun W, Yuan X, Tian Y, et al. Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer. J Hematol Oncol. 2015;8:95. doi:10.1186/s13045-015-0193-6
   PubMed Web of Science ®Google Scholar
• Jiang T, Ren S, Zhou C. Role of circulating-tumor DNA analysis in non-small cell lung cancer. Lung Cancer. 2015;90(2):128–134.
   PubMed Web of Science ®Google Scholar
• Pasquale R, Fenizia F, Esposito Abate R, et al. Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients. Pharmacogenomics. 2015;16(10):1135–1148.
   PubMed Web of Science ®Google Scholar
• Reck M, Hagiwara K, Han B, et al. Investigating the utility of circulating-free tumour-derived DNA (ctDNA) in plasma for the detection of epiudermal growth factor receptor (EGFR) mutation status in European and Japanese patients (pts) with advanced non-small cell lung cancer (ANSCLC): ASSESS study. Ann Oncol. 2015; doi:10.1093/annonc/mdv128. 1-Abstr 350_PR
   Web of Science ®Google Scholar
• Ilie M, Hofman V, Long E, et al. Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? Ann Transl Med. 2014;2(11):107. doi:10.3978/j.issn.2305-5839.2014.08.11
   PubMedGoogle Scholar
• Shen Y, Tang D, Yao R, et al. MicroRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation. Med Oncol. 2013;30(4):750. doi:10.1007/s12032-013-0750-1
   PubMed Web of Science ®Google Scholar
• Li B, Ren S, Li X, et al. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer. Lung Cancer. 2014;83(2):146–153.
   PubMed Web of Science ®Google Scholar
• Sholl LM, Xiao Y, Joshi V, et al. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clin Pathol. 2010;133(6):922–934.
   PubMed Web of Science ®Google Scholar
• Eberhard DA, Giaccone G, Johnson BE. Non-small-cell lung cancer working group. Biomarkers of response to epidermal growth factor receptor inhibitors in non-small-cell lung cancer working group: standardization for use in the clinical trial setting. J Clin Oncol. 2008;26(6):983–994.
   PubMed Web of Science ®Google Scholar
• Ellison G, Zhu G, Moulis A, et al. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol. 2013;66(2):79–89.
   PubMed Web of Science ®Google Scholar
• Thress KS, Brant R, Carr TH, et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer. 2015;90(3):509–515.
   PubMed Web of Science ®Google Scholar
• U.S. FDA News Release: FDA approves new pill to treat certain patients with non-small cell lung cancer. [cited 2016 Jan 21]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472525.htm.
   Google Scholar
• Ishii H, Azuma K, Sakai K, et al. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples. Oncotarget. 2015;6(31):30850–30858.
   PubMed Web of Science ®Google Scholar
• Pender A, Garcia-Murillas I, Rana S, et al. Efficient genotyping of KRAS mutant non-small cell lung cancer using a multiplexed droplet digital PCR approach. PLoS One. 2015;10(9):e0139074.
   Google Scholar
• Sriram KB, Tan ME, Savarimuthu SM, et al. Screening for activating EGFR mutations in surgically resected nonsmall cell lung cancer. Eur Respir J. 2011;38(4):903–910.
   PubMed Web of Science ®Google Scholar
• Marchetti A, Del Grammastro M, Felicioni L, et al. Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment. PLoS One. 2014;9(8):e103883.
   PubMed Web of Science ®Google Scholar
• Dias-Santagata D, Akhavanfard S, David SS, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med. 2010;2(5):146–158.
   PubMed Web of Science ®Google Scholar
• Masago K, Fujita S, Muraki M, et al. Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations. BMC Cancer. 2015;15(1):908.
   PubMed Web of Science ®Google Scholar
• D’Haene N, Le Mercier M, De Neve N, et al. Clinical validation of targeted next generation sequencing for colon and lung cancers. PLoS One. 2015;10(9):e0138245.
   Google Scholar
• Pfarr N, Stenzinger A, Penzel R, et al. High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer. Genes Chromosomes Cancer. 2016;55(1):30–44.
   PubMed Web of Science ®Google Scholar
• Lira ME, Choi YL, Lim SM, et al. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer. J Mol Diagn. 2014;16(2):229–243.
   PubMed Web of Science ®Google Scholar
• Deeb KK, Hohman CM, Risch NF, et al. Routine clinical mutation profiling of non-small cell lung cancer using next-generation sequencing. Arch Pathol Lab Med. 2015;139(7):913–921.
   PubMed Web of Science ®Google Scholar
• Fassunke J, Haller F, Hebele S, et al. Utility of different massive parallel sequencing platforms for mutation profiling in clinical samples and identification of pitfalls using FFPE tissue. Int J Mol Med. 2015;36(5):1233–1243.
   PubMed Web of Science ®Google Scholar
• Dietel M, Johrens K, Laffert MV, et al. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. Cancer Gene Ther. 2015;22(9):417–430.
   PubMed Web of Science ®Google Scholar
• Weickhardt AJ, Aisner DL, Franklin WA, et al. Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. Cancer. 2013;119(8):1467–1477.
   PubMed Web of Science ®Google Scholar
• Shtivelman E, Hensing T, Simon GR, et al. Molecular pathways and therapeutic targets in lung cancer. Oncotarget. 2014;5(6):1392–1433.
   PubMed Web of Science ®Google Scholar
• Crystal AS, Shaw AT, Sequist LV, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science. 2014;346(6216):1480–1486.
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Combining cancer immunotherapy and targeted therapy. Curr Opin Immunol. 2013;25(2):291–296.
   PubMed Web of Science ®Google Scholar
• Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12(4):237–251.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. [cited 2106 Jan 21]. Available from: www.clinicaltrials.gov.
   Google Scholar